Latest Intelligence on Oncology in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Potential lung cancer epidemic looming in Asia

Lung cancer is the leading cause of cancer-related mortality throughout much of the industrialized and developing world. Smoking is the main cause of lung cancer, but with smoking declining in most Western societies, it seems that the peak of the lung cancer incidence in the West has passed. In Asia, however, a lung cancer epidemic is looming, as more smokers die and more children take up smoking.

Published By Datamonitor
21 May 2008
CommentWire
CommentWire

Pharmion: Vidaza takes first steps in Europe

Pharmion has submitted a Marketing Authorization Application with the EMEA for Vidaza in the treatment of patients with higher-risk myelodysplastic syndromes. If successful, it will become the first drug to be approved in the EU for MDS. However, Pharmion will need to establish a strong market position in the EU market in order to minimize the impact of future competition.

Published By Datamonitor
16 Jan 2008
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

Pfizer: Sutent raises the bar for Nexavar in kidney cancer

Pfizer has filed for European clearance to expand the approved indications for Sutent to include newly-diagnosed kidney cancer patients. With this filing occurring just weeks after the drug was approved as a second line treatment in renal cell carcinoma, this will increase the pressure on Bayer and Onyx Pharmaceuticals' Nexavar, Sutent's competitor in the kidney cancer market.

Published By Datamonitor
17 Aug 2006
Expert View
Expert View

Pfizer: new data bode well for potential first-in-class CDK inhibitor

Pfizer has announced positive Phase II trial data for its ER+/HER2-negative breast cancer drug PD-991. If the strong efficacy is repeated in the planned Phase III pivotal study, PD-991 is likely to generate considerable revenue in the lucrative first-line advanced and metastatic ER+/HER2-negative breast cancer treatment setting, and is well positioned to become the first-in-class CDK inhibitor.

Published By Datamonitor
07 Dec 2012
CommentWire
CommentWire

Pfizer: development setbacks cast doubt over Sutent

For the third time in 2009, Pfizer has terminated a Phase III study of Sutent, this time in metastatic colorectal cancer. Although the drug remains likely to achieve blockbuster sales within its existing approved indications, this latest setback casts further doubt over its clinical potential in larger, more lucrative indications.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Pfizer: breakthrough for neuroendocrine tumor therapy

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor
13 Mar 2009
CommentWire
CommentWire

Pfizer: Aromasin patent could dampen its potential

Clinical trial data has shown that post-menopausal women with breast cancer who were treated using Aromasin demonstrated a significantly reduced risk of recurrence and increased disease-free survival than those treated with tamoxifen. With Aromasin's patent up in 2006, Pfizer [PFE] should now concentrate on marketing this product as a second-line treatment.

Published By Datamonitor
22 Mar 2004
Expert View
Expert View

Pfizer's Celebrex may increase cardiovascular risk

Pfizer has announced that one of two long term cancer studies, Adenoma Prevention with Celecoxib (APC), has shown that patients receiving 400mg and 800mg of Celebrex (celecoxib) have a 2.5 fold increased risk of cardiovascular events compared to placebo. However, a similar trial, Prevention of Spontaneous Adenomatopus (PreSAP) revealed no greater cardiovascular risk than placebo.

Published By Datamonitor
20 Dec 2004
Expert View
Expert View

OSI's rejection of hostile takeover bid may prove costly for Astellas

Astellas has initiated legal proceedings after the board of OSI Pharmaceuticals rejected an unsolicited $3.5 billion acquisition bid by the Japanese pharmaceutical giant. With Astellas facing a slowdown in sales both domestically and internationally, the acquisition of OSI would lift its forecasts. The implications of its latest M&A efforts are, therefore, considerable.

Published By Datamonitor
03 Mar 2010

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.